➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Boehringer Ingelheim
Express Scripts
Merck
AstraZeneca

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 9,550,983

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,550,983
Title:Nucleic acid sequence segment for enhancing protein expression
Abstract: An isolated or a purified nucleic acid sequence for enhancing expression levels of a protein of interest, in 5\' to 3\' direction, comprises: a cytomegalovirus (CMV) promoter; an eEF-1 intron repeat (eEF-1 IR); and a regular sequence, which comprises: at least one tag element, a fixable linker sequence, wherein the fixable sequence is TEV sequence; and a multiple cloning site (MCS). By means of the array of the specific promoter and eEF-1 IR, the expression and purity of the recombinant protein could be enhanced; wherein eEF-1 IR can reduce the length of vector and assist RNA polymerase II transcription. Besides, TEV sequence of the fixable linker sequence of the regular sequence can remove a tag on recombinant protein; a specific target can be inserted into the multiple cloning site.
Inventor(s): Ko; Ying-Chin (Taichung, TW), Lee; Chi-Pin (Taichung, TW), Chiang; Shang-Lun (Taichung, TW)
Assignee: China Medical University (Taichung, TW)
Application Number:14/820,836
Patent Claims:see list of patent claims

Details for Patent 9,550,983

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial China Medical University (Taichung, TW) 2035-03-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial China Medical University (Taichung, TW) 2035-03-27 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial China Medical University (Taichung, TW) 2035-03-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
McKinsey
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.